Ever wonder what kind of impact the leading diabetes advocacy organizations are really having? So do we.

That’s why it’s a tradition here at the ‘Mine at the start of each new year to ask a group of the most influential U.S. diabetes nonprofits point-blank: What did they actually achieve over the past year? And what do they plan to make happen in the year ahead?

Below are the answers from the various leaders and spokes-folks of the second crop of these 13 orgs. In case you missed it, yoy can read the first half that we published last week.


In February, we unveiled our new Strategic Plan, focusing on three pillars — drive discovery, raise voice and support people — that are at the core of everything we do. As part of this strategy, the ADA, under our new Chief Scientific, Medical and Mission Officer Dr. William T. Cefalu (who began in February 2017), realigned several departments within the organization to streamline our efforts and broaden our impact in communities across the country.

Protecting Access to Affordable Care: Throughout the year, the ADA worked to keep in place the patient protections that the Affordable Care Act (ACA) enacted and to ensure that people with diabetes had access to adequate, affordable health coverage. The ADA took a strong public stance, releasing several media statements throughout the year and sending letters to Congressional leadership to urge for comprehensive solutions. The Federal Affairs team met with Congressional staff on both sides of the aisle, and we activated our network of nearly half a million diabetes advocates to raise their voices through direct contact with their representatives. Additionally, we worked alongside several leading patient and consumer organizations on coalition efforts to emphasize the impact that ACA repeal would have on people living with chronic illnesses. Despite the recent repeal of the individual mandate in the 2017 Tax Cuts and Jobs Act, the ADA will continue to work with Congress to ensure that health care policies address the needs of people with or at risk for diabetes.

Call to Congress 2017: More than 180 diabetes advocates, researchers and professional football players (representing the ADA’s Team Tackle initiative) from across the country convened on Capitol Hill for the ADA’s annual Call to Congress Advocacy Day on March 30. The group represented 33 states and held more than 188 meetings with Congressional offices to urge policymakers to increase research funding, make insulin affordable and ensure that diabetes is a national priority. The event included a press conference where we delivered the Make Insulin Affordable petition, with 235,000 signatures, to Senators Jeanne Shaheen (D-NH) and Susan Collins (R-ME).

77th Scientific Sessions: Our annual Scientific Sessions continued to bring together the world’s best and brightest scientific minds to share cutting-edge research on nearly every aspect of diabetes. Hosted in San Diego this year, the five-day meeting drew nearly 17,000 researchers, physicians, health care professionals, advocates and media to discuss the latest and most important research findings. Highlights from the sessions can be found on our blog here.

Insulin Affordability: In the year since our Make Insulin Affordable campaign launched, we have held more than 200 Congressional meetings with our diabetes advocates; collected more than 600 patient, caregiver and provider stories; and had more than 265,000 people sign our petition, which was delivered to the co-chairs of the Senate Diabetes Caucus in March. We have also convened an Insulin Access and Affordability Working Group that has been meeting all year with stakeholders at all levels of the supply chain in an effort to understand the underlying causes that have led to the rapid rise in insulin prices. In 2018, we plan to share the knowledge we have gained about the insulin supply process and our proposed solutions for lowering the cost of insulin.

Diabetes is Not a Choice: In May, White House Office of Management and Budget Director Mick Mulvaney made comments about people with diabetes that perpetuated the stigma that one chooses to have diabetes based on his/her lifestyle. We felt these comments were inappropriate given our knowledge of the science behind diabetes, and also opposed any implication that access to health care should be rationed or denied to anyone, regardless of their health status. We responded swiftly, taking this opportunity to educate the public and our nation’s leaders on the many risk factors that can lead to diabetes and to change the national dialogue about this chronic illness that affects 1 in 11 Americans. With our “Diabetes is Not a Choice” campaign, we are dispelling myths and misconceptions about diabetes and telling the world that no one chooses this disease.

Hurricane Relief for People with Diabetes: In response to the catastrophic impact of Hurricanes Harvey, Irma and Maria, the ADA convened leading diabetes organizations to address the needs of people with diabetes, many of whom had no electricity, suffered severe damage to their homes, or were evacuated to shelters. Given these conditions, many were faced with the reality of not having sufficient insulin, insulin supplies, glucose testing equipment or other medications as required to maintain health. Working together, the Diabetes Emergency Relief Coalition (DERC)—comprised of the ADA, JDRF, Insulin for Life USA, Endocrine Society, American Association of Clinical Endocrinologists, American Association of Diabetes Educators, Research! America and T1D Exchange—provided thousands of pounds of diabetes supplies to people in Texas, Florida, Louisiana, Puerto Rico and the Caribbean.

The ADA Call Center, 1-800-DIABETES, responded to hundreds of calls for help, and staff, volunteers and coalition partners reached out to program participants, camp families, and donors to ensure that affected communities had access to the diabetes supplies and resources they needed. A hotline, 1-314-INSULIN, was also set up for health care providers in need of diabetes supplies and insulin for patients. In addition, the ADA website posted and regularly updated lists of resources and information specific toaffected areas in both English and Spanish, as well as links for people wishing to donate diabetes supplies to the relief effort. The DERC partners are working together to assess the impact of their efforts and develop a thorough emergency relief plan focused on supporting people with diabetes in the aftermath of natural disasters.

Updated Standards of Care: Released each year, the ADA’s Standards of Medical Care in Diabetes outline comprehensive recommendations that reflect the latest advances in evidence-based research. The 2018 Standards include notable recommendations for people with cardiovascular disease and diabetes, as well as the integration of new technology into diabetes management and routine screening for type 2 diabetes in high-risk youth. If there is new data that becomes available that will alter or improve clinical care that is validated by the Professional Practice Committee, necessary annotations in the Standards will be made. In addition, the ADA will be offering the Standards as a user-friendly and interactive app for both web and mobile devices.

National Diabetes Prevention Program Expansion: The Centers for Disease Control and Prevention (CDC) awarded the ADA a five-year, cooperative agreement to support the expansion of the National Diabetes Prevention Program (National DPP) to underserved areas in the U.S. In the first year of the award, the ADA will lead program expansion at five sites in Arizona, California and Texas. The ADA’s multi-state network will be available to anyone with prediabetes, and the sites selected will be in areas of most need to serve Hispanic and older adults with prediabetes and where there are limited or no access to existing National DPP providers. The ADA’s multi-state network will seek to reach 1,000 individuals in the first year across all five sites.


We will continue to fight to protect the rights of people with diabetes through our legal advocacy efforts on the federal, state and local level. We will raise our collective voices to ensure that people with diabetes have access to adequate, affordable care and that funding for diabetes research is increased and that the diabetes epidemic is a national priority for our nation’s leaders. We will debut new resources for people living with and at risk for diabetes, including the living Standards of Care; interactive online tools for newly diagnosed type 1 families; and an online Food Hub with diabetes-friendly recipes and nutritional information.


Continuing our sole focus on discovering a biological cure, the DRI made progress in its three key BioHub research areas – Site, Sustainability and Supply – and received FDA approval to proceed with several new clinical trials, and others pending approval, the majority of which will test innovative immunotherapies to combat the immune system in T1D.

  • We are set to begin a patient study using low doses of IL-2 (Interleukin-2) in young people (age 12-21) who have had diabetes onset in the past 4-12 months. The trial will enable us to understand the potential impact of IL-2 in promoting islet cell survival by restoring immune system balance and preventing beta cell destruction.
  • In a first step toward reversing autoimmunity in T1D with a combination therapy, patients (age 18-35) with recent diagnosis (within 4 months) will be eligible for a clinical trial (DIPIT) using four drugs (short course ATG for immunomodulation, anti-TNF to reduce inflammation, IL-2 to promote regulatory immunity, and a GLP-1 agonist to improve beta cell health). This combination will be tested for safety and efficacy.
  • A clinical protocol in the final stages of development will address the role of combination therapy with high-dose omega 3 fatty acids and vitamin D on the progression of disease in patients with new onset (≤6 months) or established (>6 months) T1D. Inflammation has shown to play a significant role in T1D development, and “safe” anti-inflammatory strategies initiated either early at onset or later in the disease process may have a positive impact.
  • A clinical protocol, “Pancreatic islet transplantation into the anterior chamber of the eye,” was also granted regulatory approval to proceed. This will further islet transplantation research in the treatment of T1D patients by demonstrating the efficacy of intraocular islet transplantation as it relates to the control of blood glucose levels in patients.

Sustainability – progress made in otherresearch projects aimed at halting autoimmunity and protecting transplanted islets includes:

  • Among the several approaches underway at the DRI to boost the levels of Treg cells is a project that involves the infusion of islet-specific Tregs, which has resulted in 100% remission of autoimmunity and diabetes and promoted long-term tolerance without the chronic use of immunosuppression in experimental models.
  • The biomedical engineering team has continued to translate its conformal coating encapsulation approach and this past year published data showing the importance of minimizing the size and thickness of the capsules to allow insulin secretion. They also demonstrated that this immunoisolation technology allows for long-term survival of islets without immunosuppression in experimental models.
  • Researchers identified a subpopulation of Mesenchymal Stem Cells (MSCs) that possesses a unique immunoregulatory capability. These particular “helper cells” may be an important cellular tool to induce tolerance when co-transplanted with islets. These preliminary findings will be translated from the bench into experimental models in the coming months.
  • The drug discovery team mapped out the biochemical changes that occur during T1D onset and also pinpointed early biomarkers of T1D in experimental models. Currently, there is no good biomarker to detect whether the immune attack on the beta cells is underway. Therefore, identifying these metabolic signals is important not only for preventing diabetes onset, but also for monitoring and addressing the recurrence of immune attack in islet transplant patients or those being treated with T1D immunotherapies. The team also made progress in designing new molecules for safer and more targeted immunosuppressive agents to protect transplanted islets, with results showing promise in early experimental testing.


  • Our initial experience under this BioHub protocol has demonstrated feasibility and safety of clinical islet transplantation within a biologic scaffold in an alternative site. Insulin independence was achieved for up to 15 months in one subject, published in the New England Journal of Medicine, and stable glycemic control and positive C-peptide were observed in two other subjects. Long-term follow-up and additional transplants using this protocol are planned and will be of assistance to determine safety and long-term efficacy of this novel transplant strategy.


  • The DRI’s cell supply team has fully identified the human stem-like cells within the pancreas that have the ability to become insulin-producing cells in response to BMP-7, an FDA-approved molecule. They have also identified their location within specific pancreatic ducts and submitted these findings for publication.


  • Continuation of BioHub Trial to transplant islets in the omentum and expansion of the clinical trials to international DRI Federation Centers.
  • Patient screening and enrollment of potential candidates for the DRI’s four new clinical trials (Low-dose IL-2, DIPIT, POSEIDON, and Intraocular islet transplant) will be underway in 2018.
  • The DRI’s multidisciplinary teams involved in the projects mentioned above, among other cure-focused initiatives, will be working to further advance and translate their findings closer to patient testing.


  • Continued growth of our Minority Initiative Program, including in-person services for women in underserved populations (African-American and Hispanic), with more Spanish-speaking programming
  • Continued growth of our signature PODS Meetup Program, training more women leaders to represent DiabetesSisters in their communities through peer support and education
  • Continued growth of our annual Leadership Institute, empowering women to lead and inform other women on how to live better with diabetes
  • Continued growth in our online presence through Facebook, Twitter and Instagram
  • Launch of a National Strategic Partnership program with industry leaders, to help guide initiatives beyond 2018


Advocacy: Our work focused mainly on maintaining the momentum from our previous advocacy efforts with the Beyond A1c movement with the FDA. In July 2017, we gathered leaders in the diabetes community to host a discussion on “Glycemic Outcomes Beyond A1c: Standardization and Implementation.” The purpose was to highlight the consensus on glycemic metrics for researchers and to advocate for regulatory change; the meeting was attended by representatives from AACE, ADA, ATTD, EASD, EMA, Endocrine Society, FDA, IHSG, and JDRF as well as industry and patient groups.

Diabetes Prevention: In September 2017, we published the “Anthology of Bright Spots,” a compilation of programs that have demonstrated success in preventing type 2 diabetes. This was the culmination of over 800 hours of interviews and research on hundreds of different programs. It highlights over 50 prevention programs and provides detailed analysis of what drives the success of each one.

diaTribe Newsletter: diaTribe,our online publication offering actionable updates and resources for people with diabetes and their loved ones, reached more people than ever in 2017. Notably, we went from a twice-a-month to a weekly newsletter, allowing us to send over 25 newsletters in 2017, a 30% increase from 2016. These newsletters are now reaching nearly 140,000 subscribers, a 35% increase from 2016. We were also eager to expand our topic coverage, writing original pieces on issues of access, doing deep dives on Medicare, workplace insurance and benefits, and financial assistance for people with diabetes. We have also welcomed a new columnist to diaTribe, Catherine Newman, who has written several pieces on recipes for healthy eating – which readers have indicated in our annual survey is a top priority.

Bright Spots & Landmines: In 2017, The diaTribe Foundation published Bright Spots & Landmines: The Diabetes Guide I Wish Someone Had Handed Me (free PDF or $6 on Amazon). The book provides actionable advice on diet, exercise, mindset, and sleep. It is in the hands of over 35,000 people – 80% have received it for free! – and has been reviewed/mentioned in The Huffington Post, US News & World Report, Diabetes Forecast, The American Journal of Managed Care, Endocrine Today, Medscape, Clinical Diabetes, DiabetesMine, A Sweet Life, JDRF UK Magazine, and many more print outlets and podcasts.

Speaking & Outreach: Kelly and Adam delivered and led over 30 speeches and panel discussions at influential conferences throughout the year. Their commitment to education and advocacy has resulted in speaking engagements all over the world, from Washington D.C. to Lisbon to Abu Dhabi. In addition, Kelly Close wrote over 25 blog posts, which feature her insights and opinions on public health issues ranging from soda taxes to how built environments affect individual and societal health.

d17: In September 2017, we hosted our second event in the dSeries, an innovation lab that brings together the leaders not only in diabetes but also other fields that have the potential to improve outcomes. We had over 75 participants and more than 100 brilliant ideas – in our humble opinion – some of which we are turning into projects for the near future!

Staffing and the TdF Board: In 2017, we were excited to hire our first Managing Director to The diaTribe Foundation, as well as three new associates. We were also thrilled to welcome Marjorie Sennett to the Foundation’s board of directors, not to mention IDEO’s Dennis Boyle, who joined the board in early 2017.


Here is just a taste of our goals on several key programs:

Advocacy: We hope to publish the report that came out of our July 2017 meeting on glycemic outcomes, disseminate it to the entire Diabetes Community, and present a consensus for regulatory change. We are also excited to launch a new advocacy platform!

Anthology of Bright Spots Public Launch: We look forward to sharing this resource with as many groups as possible. By the end of 2018, our goal is for Bright Spots & Landmines to be in the hands of well over 50,000 people. Our team also hopes to publish an mmol/L version, a flash card version, and an audio version.

diaTribe Learn: We’re looking forward to strong growth in subscribers, readership, and content expansion.


  • JDRF announced results of the JDRF-funded CONCEPTT trial, which showed that monitoring blood sugar levels continuously during pregnancy via a continuous glucose monitor (CGM) led to significantly better health outcomes for mothers with type 1 diabetes (T1D) and their babies.
  • The results of a landmark trial testing whether blockbuster cancer drug imatinib (brand name Gleevec) found that the drug slowed the progression of T1D and the loss of the body’s own insulin production, as on average, the people who got the medicine used less insulin and had higher beta cell function.
  • The international Diabetes TrialNet Oral Insulin Prevention Trial, the largest and longest oral insulin prevention trial ever conducted, sought to answer whether treatment at early stages of disease can delay progression to clinical (stage 3) type 1 diabetes. While there was not significant evidence of efficacy in the main group tested, in one of the subgroups, oral insulin was able to delay the progression of T1D by 31 months on average.
  • The REMOVAL trial showed that the type 2 diabetes drug metformin has beneficial effects on cardiovascular and metabolic outcomes in adults with longstanding T1D, showing reduced thickening of the arteries in adults with T1D. These results are extremely relevant to the T1D community, as heart disease is the most common cause of reduced life expectancy in people with type 1 diabetes.
  • Results of ongoing clinical trials of Lexicon’s dual SGLT inhibitor sotagliflozin, a type of drug that helps avoid high blood-sugar levels by increasing excretion of glucose via urine, showed that sotagliflozin not only reduced HbA1c in adults with T1D but also improved other key health measures, such as time in range, body weight and blood pressure, without increasing hypoglycemia.
  • In January 2017, we said goodbye to our friend, T1D champion and longtime international chairman Mary Tyler Moore. In celebration of her life, JDRF established a tribute site at MooreForever.org, inviting individuals to share their memories, thoughts and appreciation for her life’s work both on and off screen.
  • More than 160 children with T1D, their parents, celebrity role models and JDRF leaders converged on Washington, D.C. for the 2017 JDRF Children’s Congress, to attend a Senate hearing and meet with their representatives in Congress to call for renewed research funding, including SDP. Efforts to renew SDP are continuing through the end of 2017.
  • Announced a collaboration with IBM to develop and apply machine learning methods to analyze years of global T1D research data and identify factors leading to the onset of T1D in children. This global data analysis project is the first precision medicine effort to identify T1D risk and onset.
  • Announced the launch of a new Type 1 Diabetes Health Insurance Guide to help people living with T1D choose an insurance plan and navigate the issues that arise in getting care and treatments covered by their plan.
  • Launched Coverage2Control campaign urging insurance companies to provide coverage that works for people with T1D. The campaign earned the support of more than 52,000 petition signers and 12 major diabetes and health groups, and led to Anthem’s decision to cover artificial pancreas technology.
  • Thanks to extensive advocacy by JDRF volunteers and staff, clinician support, and strong bipartisan support from Congress, the Centers for Medicare & Medicaid Services (CMS) determined recently that continuous glucose monitoring (CGM) devices that are approved for use in treatment decisions are eligible for Medicare coverage.
  • Supported hurricane relief as part of a coalition with Insulin for Life, ADA and several other organizations, which provided emergency support to the diabetes community affected by Hurricanes Irma, Harvey, and Maria. In total, more than five pallets weighing over 4,655 pounds, including insulin, syringes and other necessary supplies, were sent to the hardest-hit areas.
  • Released a set of healthcare principles to ensure people with T1D have access to affordable health insurance that covers the care necessary to treat their diabetes, and strongly advocated for these principles as healthcare reform was being considered in Congress.
  • Launched the JDRF T1D Fund, a new venture philanthropy vehicle and the first and largest investment vehicle devoted to identifying and funding the best early-stage high impact T1D commercial opportunities in active partnership with venture and industry capital sources.
  • Launched an Open Protocol Automated Insulin Delivery Initiative that will support the development of open protocols for artificial pancreas (AP) technology by helping to establish clear financial, regulatory and legal frameworks. By making patient-driven, DIY technology approaches more accessible to a wider group of people with diabetes, users of insulin delivery devices will be able to manage their blood glucose levels better, safely, and in a way that works best for them.
  • Rolled out the T1D Performance in Exercise and Knowledge (PEAK) program, in which a team of experts, researchers and clinicians published guidelines to help people with type 1 diabetes exercise safely and offered events to teach the benefits and challenges of exercise with T1D.


The three tenets of JDRF’s Advocacy Agenda will continue to serve as a basis for JDRF’s evolving advocacy efforts in 2018.


  • Regarding access to care, we will continue to engage in health policy in 2018 and will continue to fight for greater access, choice, innovation and affordability of T1D therapies. We’ve made a lot of inroads with private insurers this year, and we expect to do even more with Medicare in 2018 – including advocating for coverage of patch pumps, cell phones used in conjunction with CGM, and artificial pancreas technologies.
  • We plan to have an ongoing, proactive healthcare policy agenda in 2018 that advances the interests and health of people with diabetes. In 2017, we engaged health plans via the #Coverage2Control campaign and plan to continue that dialogue. Moving forward, we’ll continue to engage other stakeholders, including increased efforts to reach employers.
  • In JDRF’s Insurance Guide in 2017, we included information on how people with diabetes can advocate to their employer, but in 2018, we intend to find ways we as an organization can engage major employers and ensure they are offering the right options to employees with diabetes.
  • In regard to the Special Diabetes Program, JDRF staff and volunteers have been working over the past 18 months to secure support for passing renewed funding. We began in the summer of 2016 with advocates asking Members of Congress to sign a letter, securing the support of 75 Senators and 356 House Representatives. We continued to advocate in person at Government Day and during Children’s Congress in 2017, as well as virtually through calls to action for the T1D community to write to Members of Congress. Now, at the end of 2017, we are still pushing for the best possible outcome, both personally from the JDRF Advocacy team and with continued alerts and calls to action for the T1D community. We believe we will have new information in the next week that will allow us to determine the best next steps to advocate for renewed research funding.

Supporting Technology, Treatment & Cure Research:

  • Development of novel approaches for accelerated clinical testing of disease-modifying beta cell and immune therapies
  • Development of technologies to allow targeted delivery of therapeutics to beta cells
  • Expanding programs for general population screening for T1D risk to reduce incidence of DKA at diagnosis and identify subjects prevention clinical studies
  • Pursuing open protocol technology for Artificial Pancreas technologies, as recently announced
  • Development of smaller, next-generation patch pumps that are flexible and/or have integrated CGM. We plan to support development of smaller, lighter and Bluetooth enabled patch pumps to reduce user burden
    • Novel technologies for pumping with potential for more accurate dosing
    • Integration of (select) pump/s with CGM, thus resulting in one device (instead of 2) – a key enhancement toward reducing burden
    • We will be able to share more as project details are announced in the new year, but the RFA (request for applications) is already public
  • Development of new cell encapsulation materials that could allow for successful long-term cell replacement therapies
  • Development of novel insulins targeted to the liver to mimic non-diabetes-like physiology
  • Understanding causes of hypoglycemia through retrospective analyses of clinical trial and real-world data sets in a large public-private partnership, and identifying corrective therapies to significantly reduce the incidence of all hypoglycemic episodes


  • Hosted two Nightscout Foundation Hackathon events, with over 100 attendees devoting a full-day plus additional hours to work on open-source solutions to the problems facing PWDs.
  • Shared Nightscout with attendees of a number of regional JDRF Type One Nation events, helping tell even more people than ever that there are options out there, and that #WeAreNotWaiting.
  • Delivered another standing-room-only session at the Children with Diabetes Friends for Life conference to get attendees up to date on the latest and greatest in T1 technology
  • Supported dozens of international Nightscout Groups on Facebook, with nearly 50,000 members worldwide.
  • Operated informational booths at the ADA and AADE national conferences, where we interacted with the professionals that are driving the future of T1 care, and the companies in the market as well.
  • Supported a number of direct projects with technology and financial resources, making it possible for developers to explore ideas they might not have had the resources for previously.
  • Backed the Nightscout UK crew in their efforts to start a collection of booth and informational setups to keep spreading the word.
  • Awarded five incredible students $10,000 USD in scholarships to help drive them forward in their educational goals.
  • Hosted live streams of the “Are We There Yet in T1 Tech?” and at the DiabetesMine #DData events and other events to offer access to the entire community.


Advocacy and Representation: We will continue to advocate for open source solutions at the ADA, AADE, CWD FFL and DiabetesMine annual conferences by providing information, presentations and hands on build sessions with industry leaders, healthcare professionals and end users. We will also be LIVE-Streaming T1D related events, conferences, and tech shows to our worldwide community to expand the knowledge of available open source solutions.

Scholarships: Our goal is to expand the number of candidates and amounts given for scholarships in 2018.

Legal Protection: The Foundation will continue to provide intermediary services and protection for developers at their request.

Fundraising: As the Nightscout Foundation does not receive funding from the medical device industry, pharmaceutical industry, or any T1D-related entity, all fundraising efforts are community focused and supported.

Encourage T1D Tech Projects: We will hold two Foundation Hackathons in 2018, along with a new feature of an ‘End User Build Day’ that will follow one or both of the Hackathons, where community members will be able to gather to build some of the latest and greatest tech solutions from our worldwide community. We will also continue to provide resources (based on funding) to T1D-related tech projects and endeavors worldwide.


We worked on our traditional and newer approaches to educating, motivating and empowering people with diabetes (PWD) and their loved ones, as well as getting healthcare providers up to snuff on the important advances in diabetes management. We held eight large conferences from San Diego (our 23rd annual) to Hawaii (someone has to do it), St. Louis, Santa Clara, North Carolina, Salt Lake City, Montana and Kansas City.

The big new event that brought together 600 folks with T1D was ONE: The Ultimate Conference and Retreat for People With Type 1 Diabetes, a 3-day gathering in June. The excitement and brotherly love were palpable. Adults with type 1 need time together… plain and simple! We have a date set in mid-August for the second annual ONE and cannot wait!

We had our yearly event at the ADA (The Diabetes Forum) in collaboration with the diaTribe team. It is always held the last night of the ADA, brining in many diabetes professionals attending the meeting.

The 5th edition of the TCOYD book was just released at the end of the year in hard copy, PDF as well as eBook format. It took one year of blood, sweat and tears to get this done. It is extremely up to date and although it is written for PWD, any healthcare provider can learn a ton from it. (Note: ‘Mine editor Amy Tenderich is proud to have authored a chapter in this book!)


Our big challenge for 2018 in addition to reaching more PWD in cities across America, is to grow our online presence. Our new web site is just in the first phase with lots more to come. We have diabetes-knowledgeable folks working on content including videos and our blog. Our overarching goal is to truly touch and improve the lives of people living with diabetes and importantly also the folks who care and worry about them.

What about you, Diabetes Community?

Anything you’re happy or not-so-pleased about for this past year as to the work of these D-orgs have done, or that you’d really like to see them address in the year ahead?